Envoy Medical, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Envoy Medical, Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct a typographical error in an auditor's consent and to include updated certifications.
NASDAQ
Envoy Medical, Inc. reported a significant net loss and accumulated deficit for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite fully enrolling its pivotal clinical trial for the Acclaim CI.
NASDAQ
10-K: Envoy Medical Reports 2024 Results, Faces Going Concern Uncertainty Amidst Acclaim CI Development
Envoy Medical's 2024 10-K filing reveals ongoing losses, efforts to advance its Acclaim CI, and material weaknesses in internal controls, raising substantial doubt about its ability to continue as a going concern.
NASDAQ
Envoy Medical's 10-K filing details the rights and privileges of its Class A common stock and public warrants, including voting, dividend, and liquidation rights, as well as warrant exercise and redemption terms.